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Background: Numerous primary care innovations emphasize patient-centered processes of care. Within the context
of these innovations, greater understanding is needed of the relationship between improvements in clinical
endpoints and patient-centered outcomes. To address this gap, we evaluated the association between glycosylated
hemoglobin (HbA1c) and diabetes-specific quality of life among patients completing diabetes self-management
programs.
Methods: We conducted a retrospective cohort study nested within a randomized comparative effectiveness trial
of diabetes self-management interventions in 75 diabetic patients. Multiple linear regression models were
developed to examine the relationship between change in HbA1c from baseline to one-year follow-up and
Diabetes-39 (a diabetes-specific quality of life measure) at one year.
Results: HbA1c levels improved for the overall cohort from baseline to one-year follow-up (t (74) = 3.09, p= .0029).
One-year follow up HbA1c was correlated with worse overall quality of life (r= 0.33, p= 0.004). Improvements in
HbA1c from baseline to one-year follow-up were associated with greater D-39 diabetes control (β = 0.23, p= .04)
and D-39 sexual functioning (β = 0.25, p= .03) quality of life subscales.
Conclusions: Improvements in HbA1c among participants completing a diabetes self-management program were
associated with better diabetes-specific quality of life. Innovations in primary care that engage patients in self-
management and improve clinical biomarkers, such as HbA1c, may also be associated with better quality of life, a
key outcome from the patient perspective.
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Diabetes Mellitus is among the most prevalent chronic
illnesses in the United States, affecting nearly 24 million
Americans [1]. In response to the Institute of Medicine’s
calls for patient-centeredness [2], innovations in diabetes
care have increasingly made patients’ perspectives cen-
tral to the process and outcomes of care. These* Correspondence: anaik@bcm.edu
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reproduction in any medium, provided the oradvances, which include the Chronic Care Model [3],
the Patient-Centered Medical Home [4], and various
patient-engagement interventions [5,6], all focus on
patient-centeredness in the process of care. However,
there is a need to move beyond the process of care and
develop patient-centered outcomes to assess the impact
of these innovations from the patient perspective.
As with many chronic diseases, diabetes patients are
less concerned with clinical biomarkers [7] such as
hemoglobin A1c, blood pressure, or lipid levels, and are
more concerned with physical and social function, emo-
tional and mental health, and the burden of illness andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which include many of these domains [9] are thus more
meaningful and relevant outcomes from the patient per-
spective. The development of quality of life measures
that are associated with future clinical outcomes would
enhance shared decision making by framing treatment
options in a context that is pertinent to patients [10].
In diabetes care, general health status measures such as
the SF-36 and the EQ-5D are commonly used to assess
patients’ quality of life [11-18]. Although these measures
are useful in comparing patient health status across differ-
ent illnesses, they often cannot capture distinctive aspects
of specific diseases [19]. Quality of life measures that are
disease-specific and associated with clinical outcomes
have been developed in other chronic illnesses. For in-
stance, a number of disease-specific quality of life mea-
sures in cardiovascular disease [10,20-22] and cancer [23-
28] are predictive of subsequent morbidity and mortality.
Diabetes places significant self-management responsibility
on patients, and thus warrants the development and valid-
ation of clinically relevant and patient-centered quality of
life measures. Recent structured reviews [9,29,30] have
identified several disease-specific quality of life measures
for diabetes. Unfortunately, attempts to understand the
association between these quality of life measures and
common clinical biomarkers, such as HbA1c, have been
inadequate [9,29,30].
We conducted a retrospective cohort study nested
within a randomized comparative effectiveness trial of dia-
betes self-management interventions to investigate the as-
sociation of HbA1c and diabetes-specific quality of life.
We evaluated the relationship between diabetes-specific
quality of life and HbA1c both before and after participants
completed diabetes self-management programs.Methods
Study design
This study was a retrospective cohort study nested
within a pilot randomized comparative effectiveness trial
conducted among diabetic patients at the Michael E.
Debakey Veterans Affairs Medical Center (MEDVAMC).
The trial randomized eligible participants to the Empow-
ering Patients in Chronic Care (EPIC) goal setting inter-
vention or to a diabetes self-management and nutrition
education intervention. The primary study was con-
ducted among 50–90 year old type II diabetes mellitus
patients with primary care providers (PCPs) within the
VA healthcare system. This secondary analysis included
all participants from the original study who had HbA1c ≥
7.0% at baseline, completed either of the two self-
management programs, had HbA1c measurements in the
VA clinic database at one-year follow-up, and returned
completed one-year follow-up questionnaires.Diabetes self-management programs
All participants in our retrospective cohort completed one
of two diabetes self-management programs. Both programs
were conducted in group settings, included diabetes self-
management education, and focused on educating partici-
pants about key clinical indicators in diabetes and the im-
portance of integrating patient self-management into daily
life. Each program included a ten minute one-on-one
session with either a clinician or a diabetes educator to go
over participants’ individual HbA1c, blood pressure, and
cholesterol levels. The aim of the 1-on-1 personal sessions
in both programs was to help participants individualize the
diabetes self-management information. The Empowering
Patients in Chronic Care (EPIC) intervention included di-
dactic and problem-based discussions on goal-setting and
action planning as well as patient-physician communica-
tion. The traditional diabetes education intervention
included information on diabetes medications, associated
health problems, meal preparation, and portion size and
control. The complete methodology of the randomized
comparative effectiveness study has been published else-
where [6].
Data collection
All data used in this study were collected during the
EPIC pilot randomized comparative effectiveness trial
after approval from the Baylor College of Medicine Insti-
tutional Review Board and the MEDVAMC research and
development committee. No additional data were col-
lected for this retrospective cohort study.
Clinical information, including hemoglobin A1c and
body mass index, was collected and then extracted from
participants’ medical record in the MEDVAMC clinic
database. Participants also completed questionnaires with
a variety of self-reported data at baseline and one-year.
Diabetes-related burden of illness was assessed at baseline
as a proxy for diabetes-specific quality of life using a
measure adapted from the Diabetes Care Profile Section
VII [19]. This 13-item measure asks participants about
aspects of their daily lives that diabetes interferes with, the
burden of diabetes on personal finances, and how difficult
life with diabetes is. Responses are along a 5-point Likert
scale, with higher scores indicating a greater diabetes-
related burden of illness. Individual diabetes burden of ill-
ness scores are calculated as the mean of all items, and
thus range from 1–5. A co-morbidity score was deter-
mined using a measure derived from the Deyo modifica-
tion of the Charlson Comorbidity Index [31].
Diabetes-39: A diabetes specific quality of life questionnaire
Diabetes-related quality of life was assessed at one-year
using the Diabetes-39 [32]. This 39-item self-administered
instrument measures patients’ self-assessed quality of life,
and includes 5 domains: diabetes control, anxiety and
Table 1 Descriptive Statistics for N= 75 Patients
Mean (SD) Median (IQR)
Age in years 64.03 (7.56) 63.00 (9.00)
Baseline Burden of illnessb 2.61 (0.81) 2.77 (1.30)
Baseline Body mass index (n = 66) 33.38 (5.86) 32.16 (5.59)
Deyo comorbidity index (n = 71) 3.66 (2.55) 3.00 (3.00)
Hemoglobin A1c %
Baseline 8.82 (1.20) 8.60 (1.40)
1-year 8.28 (1.40) 7.90 (1.40)
1-year Diabetes QOL
Overall 41.36 (23.32) 40.33 (35.05)
Diabetes control 42.24 (26.90) 43.06 (48.62)
Anxiety/worry 37.94 (30.25) 37.50 (58.34)
Social burden (n = 74) 23.96 (26.32) 13.33 (40.00)
Sexual functioning (n = 74) 60.65 (34.34) 66.67 (50.00)
Energy and mobility 43.10 (25.83) 43.33 (41.11)
Frequency (Percent)
Male 73 (97.33)
Race/Ethnicity (n = 74)
White 38 (51.35)
Black 21 (28.38)
Hispanic 12 (16.22)
Other 3 (4.05)
Education Levela
≤ High School 21 (28.00)
Some College/Trade School 54 (72.00)
VA co-pay
Required 25 (33.33)
Waived 50 (66.67)
a Highest completed education level.
b Adapted from a subscale of the Diabetes Care Profile (Fitzgerald 1996).
SD= standard deviation; IQR= inter-quartile range.
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mobility. Respondents were asked “how much was the
quality of your life affected by” a wide range of aspects of
diabetes illness and its treatments in the past month. Pos-
sible responses are along a 7-point scale, and range from
“Not affected at all” (=1) to “Extremely affected” (=7). Do-
main scores were calculated by summing the responses and
then applying a linear transformation to a 0–100 scale. An
overall quality of life score was calculated using all 39 items
in the questionnaire. Scores closer to 0 indicate a better
quality of life. The instrument has undergone tests for in-
ternal consistency (Cronbach’s alpha=0.81–0.93; item-total
correlation=0.50–0.84), construct validity using the SF-36
Health Status Questionnaire, and a factor analysis, which
found that five factors accounted for 90% of variance [33].
Statistical analysis
We used descriptive statistics to characterize the cohort at
baseline. Normality of continuous variables was assessed
with Shapiro-Wilks test. Continuous variables were
described using means, standard deviations, medians, and
interquartile ranges, whereas categorical variables were
described using counts and percents. Those who returned
the follow-up survey at one year were compared to those
who did not return the survey on demographic and clin-
ical characteristics using Fishers Exact Test and the Wil-
coxon Mann–Whitney test. The Wilcoxon signed rank
sum test was used to compare change in HbA1c from
baseline to one-year follow-up and the Spearman Brown
correlation (rsb) was calculated to assess the relationship
between one-year HbA1c and overall quality of life.
Multiple linear regression models were created to assess
the relationships between change in HbA1c from baseline
to one-year and quality of life at one-year. Change in
HbA1c was calculated by subtracting baseline scores from
1 year scores. Therefore, higher scores indicated less im-
provement in HbA1c. Six regression models were con-
ducted to separately predict the overall quality of life score
and each of the five quality of life subscales. Treatment
group (where diabetes education= 0 and EPIC interven-
tion= 1) and baseline burden of illness were included as
covariates in all six models. Because baseline Diabetes-39
quality of life scores were not available, baseline burden of
illness served as a proxy for baseline quality of life. All
analyses were performed using SAS software, version 9.2
(SAS Institute Inc, Cary, NC).
Results
Sample characteristics
We identified a cohort of participants completing one of
two diabetes self-management programs as part of a ran-
domized comparative effectiveness trial. The current
study draws from the 94 participants who were con-
sented and enrolled as part of the original comparativeeffectiveness trial. We excluded 14 participants from our
cohort who did not return one-year follow-up question-
naires. Four additional participants were excluded for
having baseline HbA1c below 7.0%, and one participant
was excluded due to an incomplete D-39 questionnaire.
A total of 75 participants were included in the analytical
cohort for this study.
Table 1 describes the baseline characteristics of the study
cohort. Those with baseline HbA1c of at least 7.0% who did
not return the follow-up questionnaire (n=11) were not
significantly different from study includes (n=75) on any of
the demographic or clinical characteristics reported in
Table 1 (all ps> .05, data for non-respondents not reported).
The cohort was predominantly older men of diverse educa-
tion and racial/ethnic backgrounds, with multiple morbid-
ities and elevated BMI and HbA1c levels at baseline.
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Significant improvements in HbA1c levels were observed
for the cohort from baseline to one-year follow-up,
S=−574, p= .001. At follow-up, mean scores for overall
quality of life and diabetes control, anxiety and worry, and
energy and mobility subscale scores were similar to each
other. Social burden subscale scores were better than
overall quality of life scores, while sexual functioning sub-
scale scores were worse than overall quality of life scores.
Higher one-year HbA1c scores were associated with
worse overall quality of life (rsb= 0.37, p= 0.001). We
conducted a series of six multiple linear regression mod-
els to assess the relationship between change in HbA1c
from baseline to one-year and Diabetes-39 quality of life
(overall and for each subscale) at one-year. Results are
presented in Table 2, with all models adjusting for bur-
den of illness at baseline and treatment group. Irrespect-
ive of intervention group assignment and baseline
burden of illness, improved HbA1c levels from baseline
to one-year follow-up were significantly associated with
greater quality of life on the diabetes control (β = 0.23,
p= .04) and sexual function subscales (β = 0.25, p= .03).
Change in HbA1c from baseline to one-year was not
associated with greater overall quality of life or the anx-
iety/worry, social burden, or energy and mobility sub-
scales. The R2 values for the diabetes control, sexual
function, and energy and mobility subscale models were
significant, indicating that these models explain a signifi-
cant amount of the variability in their respective
diabetes-specific quality of life subscales.
Discussion
We constructed a retrospective cohort of participants
drawn from a randomized comparative effectiveness
study to evaluate the relationship between change in
HbA1c and Diabetes-39 quality of life. HbA1c at one-year
follow-up was significantly associated with overall qual-
ity of life on the Diabetes-39. Our multiple linear regres-
sion models suggest that improvements in HbA1c amongTable 2 Multiple Regression Models Predicting Overall QOL a
Overall
QOLa
β p
Change in Hemoglobin A1c (baseline – 1 year) b .17 .13 .
Covariates
Treatment Condition c (0 =DM education; 1 = EPIC) -.05 .68 -
Baseline Burden Inventory .36 .002 .
R2 .18**
a Lower scores indicate better quality of life.
b Lower scores indicate more improvement.
c Treatment Condition = randomization to either Diabetes Mellitus (DM) Education G
* p< .05, ** p< .01.patients completing diabetes self-management interven-
tions are significantly associated with increased quality
of life on the diabetes control and sexual functioning
subscales of the Diabetes-39. No association was estab-
lished between changes in HbA1c and the anxiety and
worry, social burden, and energy and mobility subscales.
Baseline burden of illness, a proxy for baseline quality of
life, predicted overall quality of life as well as all sub-
scales of the Diabetes-39, as expected.
This study firmly establishes the relationship between
improved HbA1c, a critical clinical biomarker in diabetes,
and the Diabetes-39, a patient-centered diabetes-specific
quality of life measure among patients completing a self-
management education program. Several previous studies
have attempted to explore the relationship between clin-
ical indicators, such as HbA1c, and a variety of diabetes-
specific quality of life measures [31,34-40]. Unfortunately,
these associations have been weak [41] or nonexistent
[42], present for only very few of a scale’s domains [36], or
are specific to type 1 diabetes only [34,35]. Further, prior
studies report on measures that have poor evidence for
validity and reliability [32,35,36,41], focus on singular
aspects of quality of life (e.g., distress [37,38,41]), ignore
key components of quality of life such as physical and so-
cial functioning [9], or include several items that are not
diabetes-specific [9]. Additionally, several reviews of
diabetes-specific quality of life measures [9,29,30] have
recognized the lack of empirical evidence on the respon-
siveness of these scales to changes in health status.
This analysis of HbA1c and diabetes-specific quality of
life addresses many of the limitations of prior studies. The
Diabetes-39 diabetes-specific quality of life measure has
been recommended for use in research and clinical settings
by all of the aforementioned reviews of diabetes-specific
quality of life measures [9,29,30]. The instrument has good
evidence for validity and reliability, includes several
domains that cover many aspects of quality of life, and is
applicable to a wide population of patients [9,29,30,33].
The Diabetes-39 is one of few diabetes-specific quality ofnd QOL Subscales at One Year (N =75)
Diabetes
Control
Anxiety/
Worry
Social
Burden
Sexual
Function
Energy and
Mobility
β p β p β p β p β p
23 .04 .10 .42 .10 .40 .25 .03 .05 .64
.04 .74 -.04 .71 -.05 .70 -.03 .81 -.07 .54
37 .001 .27 .019 .24 .04 .24 .04 .35 .003
.21** .10 .08 .14* .14*
roup Intervention or Empowering Patients in Chronic care (EPIC) Intervention.
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changes in health status [39]. Further, this instrument does
not impose a definition of quality of life upon respondents,
but instead allows patients to frame responses in the con-
text of their own personal conceptualization of quality of
life. Also, patients were directly involved in the selection of
items for the questionnaire [33]. These attributes make the
instrument highly patient-centered, one of the most critical
components to any patient-assessed quality of life measure.
Thus, our study focuses on a diabetes-specific quality of life
measure that is a prime candidate for analysis.
Our statistical methods also address several prior studies’
shortcomings. While most previous attempts to examine
the relationship between HbA1c and quality of life used
simple linear correlations [34,41,42], our analyses included
predictive linear regression models. This allows for a more
robust analysis and provides a quantification of the impact
of HbA1c on quality of life. To our knowledge, two prior
studies have employed linear regression models to assess
this relationship [37,38]. However, one study [38] grouped
continuous HbA1c data into two groups. This reduces a
model’s ability to quantify the effect of changes in HbA1c
on quality of life, and diminishes the overall robustness of
the model. A second study [37] modeled HbA1c as the pri-
mary dependent variable. This is not in line with the Insti-
tute of Medicine’s vision [2] in which patient-centered
measures, such as quality of life, are the ultimate outcomes
of care. Our analysis included a regression of continuous
HbA1c data with quality of life as the primary outcome.
Few prior studies have examined the relationship between
clinical indicators and diabetes-specific quality of life mea-
sures among participants who all completed diabetes self-
management programs. These programs were deeply em-
bedded in primary care. One program was led by a primary
care physician, while the other was led by nurse educators
and registered dieticians. The latter model represents the
type of delivery system redesign that is characteristic to
many primary care innovations [3,4]. Our examination of
the relationship between clinical indicators and quality of
life outcomes in the context of patient-centered diabetes
self-management programs demonstrates that HbA1c
improvements among participants in these programs are
associated with better quality of life. Previous studies have
included diabetes-specific quality of life among outcome
measures [40,43]. These studies approach both quality of
life and HbA1c as distinct outcomes, and do not explore the
association between the two variables. Unlike prior studies,
our study examines the relationship between changes in
HbA1c and diabetes-specific quality of life. In the post-
ACCORD era, there has been reduced emphasis on inten-
sive HbA1c control [44]. However, the current study sug-
gests that improved HbA1c resulting from diabetes self-
management interventions is associated with better
diabetes-specific quality of life. Thus, HbA1c control isrelevant to patient-centered outcomes and should remain a
valuable goal in diabetes care.
There were limitations to our study. A sample size of 75
limited the range of analytic strategies that could be
employed. The sample size may also have affected the
power of our analyses, which may account for the weak as-
sociation between changes in HbA1c and some of the
Diabetes-39 subscales. The generalizability of our study
may also be limited. Our sample is reflective of the United
States Veterans Administration patient population, consist-
ing largely of older patients who are predominantly male,
of older age, and have significant co-morbidities. Further,
all of the participants in our cohort participated in at least
one diabetes self-management program. Thus, we were un-
able to assess the impact of participation in these programs
on quality of life as compared with patients who did not
participate in any self-management programs. Additionally,
the lack of Diabetes-39 data at baseline precluded an
examination of the responsiveness of this diabetes-specific
quality of life measure over time. However, our analysis
does include HbA1c data from multiple time points and
includes a measure of burden of illness at baseline. Many
previous studies used cross-sectional data from one time
point [34,37,41,42]. Our analyses included HbA1c data
from both before and after participation in diabetes self-
management programs.
Future studies should be certain to collect quality of life
data both before and after diabetes self-management pro-
grams so that the responsiveness of quality of life mea-
sures can be assessed. Subsequent studies should also
include larger, more diverse samples to ensure adequate
power and generalizability. The inclusion of a control
group that does not receive any programs beyond routine
care may also allow for future examinations of the impact
of diabetes-self management programs on quality of life.
Conclusion
Improved HbA1c levels among participants in diabetes
self-management programs are associated with higher
diabetes-specific quality of life scores. These findings
suggest that innovations in primary care focused on pa-
tient engagement may not only improve traditional clin-
ical outcomes, but are associated with better patient-
centered quality of life outcomes.
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